Key result
Biguanide use and sleep apnea severity are linked to altered glucose trajectories during sleep.
Why the study?
Continuous glucose monitors provide detailed glucose data during sleep, but analyzing the effects of diabetes medications and sleep apnea severity on glucose levels is challenging due to data complexity and dimensionality.
Do diabetes medications and sleep apnea severity affect glucose trajectories during sleep in patients with type II diabetes mellitus?
Observational (n=174)
Do diabetes medications and sleep apnea severity affect glucose trajectories during sleep in patients with type II diabetes mellitus?
Biguanide medication and sleep apnea severity significantly affect nocturnal glucose trajectories in patients with type II diabetes, as demonstrated using novel statistical methods for functional data analysis.
May inform nocturnal glucose management in T2DM; leaves open causal effects and needs prospective validation.
Continuous glucose monitors (CGMs) are increasingly used to measure blood glucose levels and provide information about the treatment and management of diabetes. Our motivating study contains CGM data during sleep for 174 study participants with type II diabetes mellitus measured at a 5-min frequency for an average of 10 nights. We aim to quantify the effects of diabetes medications and sleep apnea severity on glucose levels. Statistically, this is an inference question about the association between scalar covariates and functional responses observed at multiple visits (sleep periods). However, many characteristics of the data make analyses difficult, including (1) nonstationary within-period patterns; (2) substantial between-period heterogeneity, non-Gaussianity, and outliers; and (3) large dimensionality due to the number of study participants, sleep periods, and time points. For our analyses, we evaluate and compare two methods: fast univariate inference (FUI) and functional additive mixed models (FAMMs). We extend FUI and introduce a new approach for testing the hypotheses of no effect and time invariance of the covariates. We also highlight areas for further methodological development for FAMM. Our study reveals that (1) biguanide medication and sleep apnea severity significantly affect glucose trajectories during sleep and (2) the estimated effects are time invariant.
No takes yet. Share an insight, caveat, or question.
Sergazinov et al. (2023) conducted an observational in Type II diabetes mellitus (n=174). Diabetes medications (biguanide) and sleep apnea severity was evaluated on Glucose trajectories during sleep. Biguanide medication and sleep apnea severity significantly affected glucose trajectories during sleep, with the estimated effects being time invariant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: